The global SMRT market, valued at $2.74 billion in 2023, is projected to reach $4.14 billion by 2031, witnessing a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating ...

Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate long ...

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be ...

Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most ...

为解决斑马鱼基因组注释不完整的问题，中国科学院水生生物研究所等机构的研究人员利用PacBio Sequel II平台对21个胚胎发育阶段进行全长转录组测序，鉴定出2113个未注释基因和33,018个新异构体，揭示了可变剪接（AS）和母源-合子转换（MZT）的动态调控特征，为脊椎动物发育机制研究提供了高分辨率 ...

研究阐明了草原生态系统的重要性及当前面临的威胁，指出野生植物转录组资源的缺乏制约了相关研究。通过PacBio Iso-Seq技术，团队成功构建了25种草原植物的全长转录组图谱，平均每个物种获得49,180条转录本，其中68.6%获得功能注释。 【方法】 ...

Grab your lab coat. Let's get started Welcome! Welcome! Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.

By Connor Hart. Shares of Sagimet Biosciences rose after the company disclosed what it called positive results from a recent clinical trial of its treatment for moderate-to-severe acne.

Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following strong trial data.

Syndeio Biosciences today announced its launch to pioneer precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous ...